Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Stoke Therapeutics (NASDAQ: STOK).The analyst commented, "Potential upside remains tied ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE